US PMA (premarket approval) for BSD's RF/microwave-based cancer therapy
This article was originally published in Clinica
Executive Summary
The US FDA has accepted for filing and review BSD Medical's premarket approval (PMA) application for its BSD-2000 cancer treatment system. The product is used to focus therapeutic radiofrequency/microwave heating in cancerous tumours in an effort to kill cancer cells and improve the response of radiation therapy, said the Salt Lake City, Utah firm.